abt-925 fumarate dihydrate

ABT-925 is a selective dopamine D3 receptor (DRD3) antagonist with an in vitro affinity approximately 100 times higher for dopamine D3 receptors than for D2 receptors.

ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.

A-437203 (Lu201640) 是一种基于1H-pyrimidin-2-one scaffold 的、具有选择性的、新型强效的d3受体拮抗剂，对 D2, D3, 和 D4 受体,的Ki 值分别为 71, 1.6 和 6220 nM。